Hydromorphone: pharmacology and clinical applications in cancer patients (original) (raw)

Abstract

Hydromorphone is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. On a milligram basis hydromorphone is five times as potent as morphine when given by the oral route, and 8.5 times as potent as morphine when given intravenously.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. The Harry R. Horvitz Center for Palliative Medicine, The Taussig Cancer Center of Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Nabeel Sarhill, Declan Walsh & Kristine A. Nelson

Authors

  1. Nabeel Sarhill
    You can also search for this author inPubMed Google Scholar
  2. Declan Walsh
    You can also search for this author inPubMed Google Scholar
  3. Kristine A. Nelson
    You can also search for this author inPubMed Google Scholar

Additional information

Electronic Publication

Rights and permissions

About this article

Cite this article

Sarhill, N., Walsh, D. & Nelson, K. Hydromorphone: pharmacology and clinical applications in cancer patients.Support Care Cancer 9, 84–96 (2001). https://doi.org/10.1007/s005200000183

Download citation